Lutetium Lu 177 dotatate

Generic name: Lutetium Lu 177 Dotatate
Brand names: Lutathera
Dosage form: intravenous solution (370 MBq/mL)
Drug class: Therapeutic radiopharmaceuticals

Usage of Lutetium Lu 177 dotatate

Lutetium Lu 177 dotatate is a radioactive medicine that binds itself to a specific part of certain tumor cells, allowing the radiation to enter and destroy those cells.

Lutetium Lu 177 dotatate is used to treat certain cancers of the digestive tract, including the stomach, pancreas, and intestines.

Lutetium Lu 177 dotatate may also be used for purposes not listed in this medication guide.

Lutetium Lu 177 dotatate side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Lutetium Lu 177 dotatate may cause serious side effects. Call your doctor at once if you have:

little or no urination;

flushing (warmth, redness, or tingly feeling);

diarrhea;

a light-headed feeling, like you might pass out;

wheezing, chest tightness, trouble breathing;

low blood cell counts--fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath; or

low potassium level--leg cramps, constipation, irregular heartbeats, fluttering in your chest, increased thirst or urination, numbness or tingling, muscle weakness or limp feeling.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of lutetium Lu 177 dotatate may include:

nausea, vomiting;

high blood sugar;

low potassium; or

abnormal liver function tests.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Lutetium Lu 177 dotatate

You should not use lutetium Lu 177 dotatate if you are pregnant or breast-feeding.

Lutetium Lu 177 dotatate can harm an unborn baby or cause birth defects if the mother or the father is receiving this medicine.

If you are a woman, use effective birth control to prevent pregnancy while you are receiving this medicine and for at least 7 months after your last dose.

If you are a man, use effective birth control if your sex partner is able to get pregnant. Keep using birth control for at least 4 months after your last dose.

Tell your doctor right away if a pregnancy occurs while either the mother or the father is receiving lutetium Lu 177 dotatate.

Do not breast-feed while receiving lutetium Lu 177 dotatate, and for at least 4 months after your last dose.

Tell your doctor if you have ever had:

kidney disease;

liver disease;

diabetes;

high blood pressure; or

any type of radiation treatment.

Lutetium Lu 177 dotatate may cause other types of cancer, such as leukemia. Ask your doctor about this risk.

This medicine may affect fertility (ability to have children) in both men and women. However, it is important to use birth control to prevent pregnancy because lutetium Lu 177 dotatate may harm the baby if a pregnancy does occur.

Relate drugs

How to use Lutetium Lu 177 dotatate

Usual Adult Dose for Neuroendocrine Carcinoma:

Intravenous infusion: 7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses.Premedication and Concomitant Medications:Somatostatin Analogs:-Discontinue long-acting somatostatin analogs (e.g., long-acting octreotide) for at least 4 weeks prior to initiating this drug. Administer short-acting octreotide as needed; discontinue at least 24 hours prior to initiating this drug.-During treatment: Administer long-acting octreotide 30 mg intramuscularly 4 to 24 hours after each dose of this drug. Do not administer long-acting octreotide within 4 weeks of each subsequent dose. Short-acting octreotide may be given for symptomatic management during treatment with this drug, but must be withheld for at least 24 hours before each dose of this drug.-Following treatment: Continue long-acting octreotide 30 mg intramuscularly every 4 weeks after completing this drug until disease progression or for up to 18 months following treatment initiation.Antiemetic-Administer antiemetics 30 minutes before the recommended amino acid solution.Amino Acid Solution:-Initiate an intravenous amino acid solution containing L-lysine and L-arginine 30 minutes before administering this drug.-Use a three-way valve to administer amino acids using the same venous access as this drug or administer amino acids through a separate venous access in the patient's other arm.-Continue the infusion during, and for at least 3 hours after infusion of this drug.-Do not decrease the dose of the amino acid solution if the dose of this drug is reduced.Comments:-Dose modifications due to adverse reactions are provided in the dose adjustment section.-Radiation Dosimetry: The maximum penetration in tissue is 2.2 mm and the mean penetration is 0.67 mm.Use: Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Warnings

Do not become pregnant or breast-feed a baby while receiving lutetium Lu 177 dotatate.

Both men and women using lutetium Lu 177 dotatate should use effective birth control to prevent pregnancy. Lutetium Lu 177 dotatate can harm an unborn baby or cause birth defects if the mother or father is using this medicine.

What other drugs will affect Lutetium Lu 177 dotatate

Other drugs may affect lutetium Lu 177 dotatate, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.